
Sign up to save your podcasts
Or


Featuring
Vlad Sandulache
Associate Professor, Baylor College of Medicine
MPI, ARTNet H-CARR U 54 Center
Dr. Sandulache is a clinician-scientist studying head and neck cancer, with a focus on treatment resistance, tumor metabolism, oxidative stress, and the biological mechanisms that determine how tumors respond to radiation and chemotherapy.
Hosted by
David Goodrich
Professor, Roswell Park Comprehensive Cancer Center
ARTNet Coordinating and Data Management Center
Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium.
Episode Summary
The conversation explores how resistance to cancer therapy may begin long before treatment starts. Dr. Sandulache discusses how head and neck tumors can be shaped by selective pressures,including metabolism, oxidative stress, environmental exposures, and immune interactions,that may precondition cancer cells to withstand radiation and chemotherapy. This perspective challenges the traditional distinction between innate and acquired resistance, suggesting that tumor evolution before treatment can profoundly influence therapeutic response.
The discussion highlights oxidative stress as a key driver of this preconditioning and explores the NRF2 pathway as an important mechanism through which tumor cells build antioxidant defenses and become resistant to therapies such as cisplatin and radiation. Dr. Sandulache also discusses opportunities to identify resistant tumors before treatment using transcriptional biomarkers, tumor biopsies, circulating DNA, and metabolic imaging, potentially allowing treatment to be tailored according to a tumor’s resistance profile.
The episode also emphasizes the value of team science within ARTNet, where investigators studying different cancers, therapies, and resistance mechanisms can bring complementary expertise to shared questions.
Key Takeaways
Featuring
Jeffrey Tyner
Professor, Oregon Health & Science University
Principle Investigator, ARTNet AML U54 Center
Dr. Tyner is a leading researcher in cancer biology and therapeutic resistance, with a focus on acute myeloid leukemia (AML), functional precision oncology, and mechanisms of acquired resistance to targeted therapies.
Hosted by
David Goodrich
Professor, Roswell Park Comprehensive Cancer Center
ARTNet Coordinating and Data Management Center
Dr. Goodrich leads discussions exploring the science, collaboration, and translational impact of cancer resistance research across the ARTNet Consortium.
Episode Summary
The conversation explores the complexity of acquired resistance in cancer therapy, emphasizing the role of cell state and cellular plasticity in driving resistance mechanisms. Dr. Tyner discusses the challenges of studying dynamic resistance processes, the promise of targeting cell state plasticity to overcome therapeutic failure, and how resistance trajectories evolve over time.
The discussion also highlights the importance of identifying the optimal window for intervention and the growing role of collaborative science within the ARTNet Consortium in advancing cancer resistance research. Despite the complexity of the problem, the episode reflects a strong sense of optimism about the future of precision oncology and translational cancer research.
Key Takeaways
Chapters
From the publisher's feed
ARTNet Podcast is the official podcast of the National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). The series features conversations with leading cancer…